As in previous studies, we observed errors in interpretation which resulted in significant morbidity [ 6, 14].
We observed errors in 10% of the SNPs, when using the standard settings of the Illumina Genome Studio software.
However, we observed errors in the data collected from SCAs in our trial which may have contributed to this discrepancy (errors were corrected for trial analyses).
By comparing 384 mesh-based measurements with manual measurements, we observed errors ranging from 5.75% to 9.34% and correlations ranging from 0.887 to 0.974.
When testing dilutions of mixed HPV/host DNA in replicate runs, we observed errors in quantifying E2 and E6 amplicons of 5 40%, with greatest error at the lowest DNA template concentration (3 ng/μl).
For the remaining sources of error, we assessed "observed" errors using a conservative approach of setting aside validation data that was never used for LiDAR calibration or carbon mapping purposes (i.e., as opposed to iterative or leave-one out techniques).
In terms of the level and pattern of errors we observed, research from the US has found a similarly high level of medication administration errors, with 'wrong time' the most frequently observed error in hospitals, skilled nursing facilities and assisted living environments [ 33- 35].
When testing for differences in the recognition of shoes, we observed higher error rates among CPs, median error rate of 24.1%, compared to controls, median of 18.4% (W = 223, n0 = 25, nCP = 13, p = 0.032 one-sided).
By masking 0.1% of the genotypes before imputation, we observed allelic error rates of 1.6% and genotypic error rates of 3.1%.
We observed an error rate of 10.9% per prescribed item, with only 56.2% of 4238 complete prescriptions remaining error free.
